179 related articles for article (PubMed ID: 8888359)
1. Biological and behavioral responses to D-amphetamine, alone and in combination with the serotonin3 receptor antagonist ondansetron, in healthy volunteers.
Grady TA; Broocks A; Canter SK; Pigott TA; Dubbert B; Hill JL; Murphy DL
Psychiatry Res; 1996 Aug; 64(1):1-10. PubMed ID: 8888359
[TBL] [Abstract][Full Text] [Related]
2. Behavioral, physiological and neuroendocrine responses in healthy volunteers to m-chlorophenylpiperazine (m-CPP) with and without ondansetron pretreatment.
Broocks A; Briggs NC; Pigott TA; Hill JL; Canter SK; Tolliver TJ; Baldemore D; Murphy DL
Psychopharmacology (Berl); 1997 Mar; 130(2):91-103. PubMed ID: 9106905
[TBL] [Abstract][Full Text] [Related]
3. Ondansetron, a 5-HT3 receptor antagonist, partially attenuates the effects of amphetamine: a pilot study in healthy volunteers.
Silverstone PH; Oldman D; Johnson B; Cowen PJ
Int Clin Psychopharmacol; 1992; 7(1):37-43. PubMed ID: 1385603
[TBL] [Abstract][Full Text] [Related]
4. Effect of the 5-HT3 receptor antagonist ondansetron on amphetamine-induced hyperactivity and stereotypy in rats.
Shankar RP; Karan RS; Handu SS; Bhargava VK
Indian J Physiol Pharmacol; 2000 Jul; 44(3):355-8. PubMed ID: 10941627
[TBL] [Abstract][Full Text] [Related]
5. The selective 5-HT3 receptor antagonist, ondansetron, augments the anorectic effect of d-amphetamine in nondeprived rats.
Cooper SJ; Greenwood SE; Gilbert DB
Pharmacol Biochem Behav; 1993 Jul; 45(3):589-92. PubMed ID: 8332620
[TBL] [Abstract][Full Text] [Related]
6. Acute and chronic role of 5-HT3 neuronal system on behavioral and neuroendocrine changes induced by intravenous cholecystokinin tetrapeptide administration in humans.
Dépôt M; Caillé G; Mukherjee J; Katzman MA; Cadieux A; Bradwejn J
Neuropsychopharmacology; 1999 Feb; 20(2):177-87. PubMed ID: 9885797
[TBL] [Abstract][Full Text] [Related]
7. Subjective responses to d-amphetamine alone and after pimozide pretreatment in normal, healthy volunteers.
Brauer LH; de Wit H
Biol Psychiatry; 1996 Jan; 39(1):26-32. PubMed ID: 8719123
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of ondansetron and alpha-flupenthixol on responding for conditioned reward.
Fletcher PJ; Higgins GA
Psychopharmacology (Berl); 1997 Nov; 134(1):64-72. PubMed ID: 9399368
[TBL] [Abstract][Full Text] [Related]
9. 5-HT3 receptor antagonism by ondansetron does not attenuate prolactin response to d-fenfluramine challenge in healthy human subjects.
Coccaro EF; Kavoussi RJ; Cooper TB; Hauger R
Psychopharmacology (Berl); 1996 Sep; 127(2):108-12. PubMed ID: 8888375
[TBL] [Abstract][Full Text] [Related]
10. Role of serotonin3 receptors in prolactin release induced by electroconvulsive therapy: a study with ondansetron.
Yatham LN; Zis AP; Lam RW; Srisurapanont M; McGarvey K; Agbayewa O
Psychiatry Res; 1996 Feb; 60(1):33-9. PubMed ID: 8852866
[TBL] [Abstract][Full Text] [Related]
11. Blockade of accumbens 5-HT3 receptor down-regulation by ondansetron administered during continuous cocaine administration.
King GR; Xiong Z; Ellinwood EH
Eur J Pharmacol; 1999 Jan; 364(2-3):79-87. PubMed ID: 9932709
[TBL] [Abstract][Full Text] [Related]
12. The effects of serotonin3 receptor blockade on the psychobiological response to intravenous clomipramine in healthy human subjects.
Leatherman ME; Bebchuk JM; Ekstrom RD; Heine AD; Carson SW; Golden RN
Biol Psychiatry; 1999 Jan; 45(2):238-40. PubMed ID: 9951573
[TBL] [Abstract][Full Text] [Related]
13. The 5-HT3 antagonist, BRL 46470 does not attenuate m-chlorophenylpiperazine (mCPP)-induced changes in human volunteers.
Silverstone PH; Cowen PJ
Biol Psychiatry; 1994 Sep; 36(5):309-16. PubMed ID: 7993957
[TBL] [Abstract][Full Text] [Related]
14. High dose pimozide does not block amphetamine-induced euphoria in normal volunteers.
Brauer LH; De Wit H
Pharmacol Biochem Behav; 1997 Feb; 56(2):265-72. PubMed ID: 9050084
[TBL] [Abstract][Full Text] [Related]
15. Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results.
Broocks A; Pigott TA; Hill JL; Canter S; Grady TA; L'Heureux F; Murphy DL
Psychiatry Res; 1998 Jun; 79(1):11-20. PubMed ID: 9676822
[TBL] [Abstract][Full Text] [Related]
16. The effect of a 5-HT3 receptor antagonist, ondansetron, on brain stimulation reward, and its interaction with direct and indirect stimulants of central dopaminergic transmission.
Montgomery AM; Rose IC; Herberg LJ
J Neural Transm Gen Sect; 1993; 91(1):1-11. PubMed ID: 8383982
[TBL] [Abstract][Full Text] [Related]
17. 5-HT3 receptor modulation of behavior during withdrawal from continuous or intermittent cocaine.
King GR; Joyner CM; Ellinwood EH
Pharmacol Biochem Behav; 1994 Mar; 47(3):399-407. PubMed ID: 8208757
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment with serotonin 5-HT(3) receptor antagonists produces no observable blockade of long-term motor sensitization to cocaine in rats.
Szumlinski KK; Frys KA; Kalivas PW
Psychopharmacology (Berl); 2003 Feb; 165(4):329-36. PubMed ID: 12451437
[TBL] [Abstract][Full Text] [Related]
19. Long-term blockade of the expression of cocaine sensitization by ondansetron, a 5-HT(3) receptor antagonist.
King GR; Xiong Z; Douglass S; Ellinwood EH
Eur J Pharmacol; 2000 Apr; 394(1):97-101. PubMed ID: 10771040
[TBL] [Abstract][Full Text] [Related]
20. Investigation of the role of 5-HT3 receptors in the secretion of prolactin, ACTH and renin.
Levy AD; Li Q; Rittenhouse PA; Van de Kar LD
Neuroendocrinology; 1993 Jul; 58(1):65-70. PubMed ID: 8264857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
